The potential cardiovascular benefits of a combined therapy involving IL-1 inhibition and lipid-modifying treatment aimed at apolipoprotein B merit further exploration, especially in individuals received IL-1Ra treatment, such as patients with RA. This evidence concerns the gene APOB and rheumatoid arthritis.